

**DECLARATION OF INVENTOR(S)
FOR UNITED STATES PATENT APPLICATION**

JUL 21 2004

ATTORNEY DOCKET NO.
V9661.0079

As a below-named inventor, I hereby declare that I verily believe that I am the original, first, and sole inventor (if only one name is listed below) or a joint inventor (if plural inventors are named) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

INHIBITION OF HEPATITIS B VIRUS (HBV) REPLICATION BY RNA INTERFERENCE

the specification of which is attached hereto, unless the following box is checked:

☐ was filed on May 19, 2004 as United States patent Application Number or PCT International patent application number 10/848,736
and
was amended on _____ (if any).

I have read and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose all information known to me to be material to the patentability of the invention in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim priority benefits under Title 35, United States Code §119 of any foreign application(s) for patent or inventor's certificate or United States provisional application(s) listed below and have also identified below any foreign application(s) for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign or U.S. Provisional Application(s)

COUNTRY	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 U.S.C. § 119
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO



I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

UNITED STATES APPLICATION NUMBER	DATE OF FILING (day, month, year)	STATUS (patented, pending, abandoned)
60/471,903	May 19, 2003	

SEND CORRESPONDENCE TO: DICKSTEIN SHAPIRO MORIN & OSHINSKY LLP
1177 Avenue of the Americas, 41st Floor
New York, NY 10036-2714

DIRECT TELEPHONE CALLS TO:
(212) 835-1400

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

FULL NAME OF FIRST INVENTOR HSIANG-FU KUNG		INVENTOR'S SIGNATURE 	DATE June 16, 2004
RESIDENCE (City and either State or Foreign Country) Hong Kong, China		COUNTRY OF CITIZENSHIP United States	
POST OFFICE ADDRESS A9, Block 1, Pine Court, 23 Sha Wan Drive			
FULL NAME OF SECOND INVENTOR MING-LIANG HE		INVENTOR'S SIGNATURE 	DATE June 16, 2004
RESIDENCE (City and either State or Foreign Country) Hong Kong, China		COUNTRY OF CITIZENSHIP China	
POST OFFICE ADDRESS 10G, Tower 28, South Horizon			



STATEMENT UNDER 37 C.F.R. §3.73(b)

Applicant/Patent Owner: Ming-Liang He et al.

Application No./Patent No.: To be assigned

Filed/Issue Date: May 19, 2004

Entitled: INHIBITION OF HEPATITIS B VIRUS (HBV) REPLICATION BY RNA INTERFERENCE

The University of Hong Kong
(Name of Assignee)

a University
Type of Assignee, e.g., corporation, partnership, university, government agency, etc.

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.
The extent (by, percentage) of its ownership interest is _____

in the patent application/patent identified above by virtue of either:

A. ☒ An assignment from the inventor(s) named in the patent application/patent identified above.

- ☒ The assignment is being submitted under a separate letter for recordation.
☐ The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (*i.e.*, the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

21 May 2004
Date

Hailson Yu
Typed or printed name

Signature

Deputy Managing Director
Title